September 27th 2024
Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
September 26th 2024
Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.